$65 Million Actelion Tracleer & Bosentan Antitrust Settlement, Check If Your Health Plan Qualifies, Claim Deadline is August 3

The Actelion Tracleer settlement is a $65,000,000 antitrust class action where eligible third-party payors — including health insurers, self-insured employer health plans, and pharmacy benefit managers — can recover money for overcharges they paid on Tracleer (bosentan) between December 29, 2015, and September 6, 2024. The case is Government Employees Health Association v. Actelion Pharmaceuticals Ltd., et al., No. GLR-18-3560, in the U.S. District Court for the District of Maryland. The claim deadline is August 3, 2026.

Quick Facts: Actelion Tracleer & Bosentan Antitrust Settlement

Field	Detail
Settlement Amount	$65,000,000
Claim Deadline	August 3, 2026 (online or postmarked by mail)
Who Qualifies	Third-party payors (health plans, insurers, self-insured employers) that purchased or reimbursed Tracleer or bosentan in covered states, December 29, 2015 – September 6, 2024
Payout Per Claimant	Pro-rata based on total spending on Tracleer/bosentan and number of valid claims
Proof Required	Yes — transaction data showing purchases and amounts paid is mandatory
Settlement Status	Proposed — pending preliminary and final court approval
Settlement Administrator	A.B. Data, Ltd.
Administrator Contact	PO Box 173072, Milwaukee, WI 53217 · 1-877-354-3839 · [email protected]
Official Website	TracleerLitigation.com
Last Updated	May 1, 2026

Current Status: Where the Actelion Settlement Stands

• The settlement agreement was filed with the court on March 4, 2026 and is currently awaiting preliminary approval.
• The opt-out deadline has already passed — December 23, 2024 — so all certified class members are bound by the settlement.
• The Fairness Hearing date, objection deadline, and final approval timeline are TBD — pending the court’s scheduling order after preliminary approval is granted. Check TracleerLitigation.com for updates.

What Is the Actelion Tracleer Lawsuit About? Gov’t Employees Health Ass’n v. Actelion Pharmaceuticals Ltd., No. GLR-18-3560

Tracleer is a brand-name prescription drug used to treat pulmonary arterial hypertension — a serious, life-threatening condition that raises blood pressure in the arteries of the lungs. The generic version of Tracleer is called bosentan. Brand drugs cost far more than generics, so when a generic is delayed, everyone who paid for the brand drug — especially health plans — pays more than they should.

The lawsuit, filed in federal court in Maryland and overseen by Chief Judge George L. Russell III, alleges that Actelion Pharmaceuticals Ltd., Actelion Pharmaceuticals US, Inc., and Janssen Research & Development, LLC violated federal antitrust laws and state consumer protection statutes by deliberately blocking generic competition. Specifically, plaintiffs allege that beginning around 2009, Actelion refused to sell Tracleer samples to generic drug manufacturers. Without those samples, generic companies could not conduct the bioequivalence testing required by the FDA to obtain approval to sell a cheaper generic version. The lawsuit claims that absent this conduct, a generic version of Tracleer would have launched before June 2019 — when the first generic actually became available — and that health plans and other third-party payors overpaid for Tracleer and bosentan as a direct result.

This is a pharmaceutical antitrust class action, a lawsuit type where third-party payors — not individual patients — are typically the class members because they bore the cost of the overpriced drug. Actelion and Janssen deny all allegations and do not admit wrongdoing. On September 6, 2024, the court certified the class over Defendants’ objections and denied Actelion’s motion for summary judgment. A trial had been scheduled for March 2026 before the parties reached this settlement. For more background on how pharmaceutical pay-for-delay litigation works, see our guide to antitrust class actions against drug manufacturers.

Who Qualifies for the Actelion Tracleer & Bosentan Settlement?

This settlement is for third-party payors only — it does not cover individual patients. If you are an individual who took Tracleer or bosentan, you are not part of this class.

You may qualify if your organization:

• Is a health insurance company, HMO, self-insured employee health or pharmacy benefit plan, or an authorized agent acting on behalf of such an entity
• Purchased, paid for, or reimbursed Tracleer (bosentan) for its members, employees, insureds, participants, or beneficiaries — not for resale
• Made those purchases or reimbursements in at least one of the covered states: Arizona, California, Florida, Illinois, Iowa, Maine, Maryland, Massachusetts, Michigan, Minnesota, Mississippi, Missouri, Montana, Nebraska, Nevada, New Hampshire, New Mexico, New York, North Carolina, North Dakota, Oregon, Rhode Island, South Carolina, South Dakota, Utah, Vermont, Virginia, West Virginia, Wisconsin, the District of Columbia, or Puerto Rico
• Purchases occurred at any time between December 29, 2015, and September 6, 2024

You do NOT qualify if:

• You are an individual patient — this class is limited to institutional third-party payors
• You are a federal or state governmental entity (cities, towns, and municipalities with self-funded prescription drug plans ARE included)
• You are Actelion, Janssen, or any of their subsidiaries or affiliates
• Your purchases were entirely outside the covered states listed above
• Your purchases were made for resale, not for consumption by plan members

If your pharmacy benefit manager (PBM) or third-party administrator (TPA) handles your plan, they may file on your behalf with prior written authorization — but confirm this directly, as the settlement administrator will only honor one claim per entity.

Related article: Did You Get a SmileDirectClub Settlement Check? Here’s Why Payments Are Arriving Now (May 2026)

How Much Can Health Plans Get from the Actelion Settlement?

Your payment from this legal settlement payout is not a fixed dollar amount — it depends on how much your plan spent on Tracleer and bosentan during the class period and how many valid claims are submitted by other class members.

Here is how the math works. After attorneys’ fees of up to 33⅓% of the $65,000,000 fund, litigation expenses, notice and administration costs, and a service award to the class representative are deducted, the remaining balance — the Net Settlement Fund — is distributed pro-rata to eligible claimants. Your share is proportional to your documented spending on Tracleer and bosentan claims net of co-pays, deductibles, and co-insurance.

The more you spent, the larger your share. The more valid claims are filed overall, the smaller each individual share becomes. Transaction data is mandatory — the settlement administrator will not pay a claim without it.

Step-by-Step: How to File Your Actelion Tracleer Claim

Step 1 — Visit TracleerLitigation.com and download the Third-Party Payor Claim Form or file online

Step 2 — Determine whether you are filing as a direct TPP class member (Section A of the form) or as an authorized agent acting on behalf of one or more TPPs (Section B)

Step 3 — Gather your transaction data covering December 29, 2015 through September 6, 2024 — this must include: drug name and NDC number, fill date, state of purchase, and the net amount your plan paid after subtracting co-pays, deductibles, and co-insurance

Step 4 — Format your data in Microsoft Excel, ASCII flat file pipe “|”, tab-delimited, or fixed-width format — an exemplar spreadsheet and list of accepted NDC numbers is available at TracleerLitigation.com

Step 5 — Submit your claim online at TracleerLitigation.com by August 3, 2026, or mail your completed form postmarked no later than August 3, 2026 to: Tracleer Litigation, c/o A.B. Data, Ltd., PO Box 173072, Milwaukee, WI 53217

Step 6 — Keep a copy of your claim form and all supporting documents. File via certified mail with return receipt if you want proof of timely submission.

Estimated time to complete: varies based on the volume of transaction data your plan needs to compile and format. Start early — transaction data retrieval can take weeks.

Important Dates: Actelion Tracleer Settlement Timeline

Milestone	Date
Lawsuit Filed	2018 (District of Maryland)
Class Period Begins	December 29, 2015
First Generic Tracleer Available	June 2019
Class Certified	September 6, 2024
Class Period Ends	September 6, 2024
Opt-Out Deadline	December 23, 2024 (passed)
Settlement Agreement Filed	March 4, 2026
Claim Filing Deadline	August 3, 2026
Objection Deadline	TBD — pending preliminary approval order from the court
Fairness Hearing	TBD — pending court scheduling
Expected Payment Date	TBD — after final court approval and resolution of any appeals

Frequently Asked Questions

Is there really a class action lawsuit against Actelion over Tracleer?

 Yes. Government Employees Health Association v. Actelion Pharmaceuticals Ltd., et al., No. GLR-18-3560, has been pending in the U.S. District Court for the District of Maryland since 2018. The court certified the class on September 6, 2024, and a $65,000,000 settlement was filed with the court on March 4, 2026.

Do I need to do anything right now to be included in the settlement?

 If you are a class member and want a payment, yes — you must file a claim with supporting transaction data by August 3, 2026. Class members who do nothing will receive no payment but remain bound by the settlement and cannot later sue Actelion for the same claims.

When will the Actelion Tracleer settlement pay out?

 Payments will go out only after the court grants final approval and any appeals are resolved. No payment date has been set — the Fairness Hearing date is still pending. Check TracleerLitigation.com for updates.

Can I file my own antitrust lawsuit against Actelion instead of joining the settlement?

 The opt-out deadline of December 23, 2024 has passed. Class members who did not exclude themselves by that date are bound by the settlement and have released their individual claims against Actelion and Janssen for the conduct at issue in this case.

How will I know when the Actelion settlement is approved?

 The settlement administrator will post updates at TracleerLitigation.com. You can also monitor the court docket at PACER under Case No. GLR-18-3560 in the District of Maryland.

Does my pharmacy benefit manager need to file separately from my health plan?

 It depends. If your PBM is filing on your behalf as an authorized agent, it must have your prior written authorization and will need to complete Section B of the claim form. If both you and your PBM submit a claim, the administrator will only honor the TPP class member’s own claim. Confirm your filing arrangement directly with your PBM now — do not assume they are handling it.

Will the Actelion settlement payment be taxable?

 Settlement proceeds may constitute taxable income depending on the nature of the claim and your organization’s tax situation. Consult your tax advisor — this article does not constitute tax advice.

What if I missed the claim deadline? 

The claim deadline is August 3, 2026 — it has not passed as of publication. If you miss it, you will receive no payment from the settlement fund. The administrator will not accept late claims. File as early as possible to allow time to resolve any documentation issues.

Sources & References

• Official settlement website: TracleerLitigation.com
• Settlement Agreement, Exhibit 1 to Robertson Declaration: Gov’t Employees Health Ass’n v. Actelion Pharmaceuticals Ltd., Case No. 1:18-cv-03560-GLR, Document 421-3 (D. Md. Mar. 4, 2026)
• Claim Form: Third-Party Payor Claim Form, Tracleer Litigation, c/o A.B. Data, Ltd.
• Court docket: U.S. District Court for the District of Maryland, Case No. GLR-18-3560, accessible via PACER

Prepared by the AllAboutLawyer.com Editorial Team and reviewed for factual accuracy against the official settlement agreement (Document 421-3, filed March 4, 2026) and the official claim form published at TracleerLitigation.com on May 1, 2026. Last Updated: May 1, 2026

Disclaimer: This article is for informational purposes only and does not constitute legal advice. Legal claims and outcomes depend on specific facts and applicable law. For advice regarding a particular situation, consult a qualified attorney.